M3 Group and Insight-I

Insight-I belongs to M3 through our IG Holdings group.

M3 is unique, combining the Internet and the real world in pharmaceutical promotion, drug/ medical device development research, medical institution support, big data business, genomic/personal medical care, and services for general consumers/patients. They are developing a wide range of dynamic companies with a new business model.

Recently, they have been developing diagnostic tools using AI, providing genomic tests. In addition, they have been expanding services beyond pharmaceutical marketing, such as making cerebral infarction rehabilitation facilities into a group company and solving medical disease issues themselves by combining them in a complex manner.

We at Insight-I are also in the healthcare field, where digital-based marketing communications are accelerating, expanding to a wide range of subjects from medical professionals to patients and general consumers. To solidify our position at the top, we will further enhance our services through alliances and collaboration with M3 and dozens of M3 group companies.

◆ M3 Co., Ltd. (https://corporate.m3.com/) operates a medical professional site "m3.com" registered by 280,000 people, which represents 90% of Japanese doctors, and provides marketing support for pharmaceutical companies. It also provides clinical trial support services. In addition to Japan, they are actively expanding overseas such as in the United States, United Kingdom, France, China, South Korea, and India. They conduct various businesses with a base of 5.5 million doctors, panelists representing half of the doctors worldwide.

◆ M3 Co., Ltd. (https://corporate.m3.com/) operates a medical professional site "m3.com" registered by 280,000 people, which represents 90% of Japanese doctors, and provides marketing support for pharmaceutical companies. It also provides clinical trial support services. In addition to Japan, they are actively expanding overseas such as in the United States, United Kingdom, France, China, South Korea, and India. They conduct various businesses with a base of 5.5 million doctors, panelists representing half of the doctors worldwide.